Media Center
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer
This is the key finding from the Phase 1/2 ENDOLUNG clinical trial, which was recently published in the prestigious scientific journal BMC Cancer.
The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 51 patients with advanced or recurrent endometrial cancer, across 9 leading oncology hospitals in Spain and France.
Ibrilatazar is an oral drug with a novel mechanism of action that induces autophagy through the induction of ER-stress and the inhibition of the PI3K/Akt/mTOR pathway, which is crucial for cellular function and is implicated in this cancer type.
The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 51 patients with advanced or recurrent endometrial cancer, across 9 leading oncology hospitals in Spain and France.
Ibrilatazar is an oral drug with a novel mechanism of action that induces autophagy through the induction of ER-stress and the inhibition of the PI3K/Akt/mTOR pathway, which is crucial for cellular function and is implicated in this cancer type.
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR
ABTL0812 has been given the International Non-proprietary Designation (INN) ibrilatazar on the recommended list of INNs issued by the World Health Organization (WHO)
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer
Joining teams and expertise, the two companies will make their mark on a new era of pancreatic cancer treatment, reaffirming their shared commitment to improving people's lives.
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer
The Canadian venture capital fund CTI Life Sciences Fund III, Inveready and the EIC Fund from the European Commission close a round with the additional participation of CDTI Innvierte, FiTalent, family offices as well as founders.
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago
Combination of ABTL0812 with chemotherapy doubles patient survival compared to historical controls with chemotherapy alone
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer
December 14, 2022
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812
November 21 , 2022
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms
November 10th, 2022
AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812
October 7, 2022
Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer
September 7, 2022
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona
June 29, 2022
AbilityPharma Will Attend the ESMO Gynaecological Cancers Congress 2022 in Valencia
June 13, 2022
AbilityPharma Will Attend BIO 2022 in San Diego as Part of the European Innovation Council (EIC) Delegation with a Booth in the European Pavilion
June 10, 2022
AbilityPharma Announces the Inclusion of the First Patient in US in the Phase 2b Part of the Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe
June 7, 2022
ABTL0812 preclinical data indicates its potential for the treatment of breast cancer
June 1, 2022
AbilityPharma Announces the Inclusion of the First European Patient in the Phase 2b Part of the Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe
April 07, 2022
AbilityPharma Announces the Successful Completion of the Phase 1 Part of its Phase 1/2b Clinical Trial in Patients with Advanced Pancreatic Cancer
February 9, 2022
Executive Chairman & CEO of AbilityPharma, Carles Domènech, is Elected as Member of the Board for the Spanish Bioindustry Association (ASEBIO) for the Second Time in a Row
December 14, 2021
The EIC Fund Has Joined the Capital of AbilityPharma with an Investment Commitment of 2.5M € as Part of the EIC Accelerator Program
December 01, 2021
Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe
May 11, 2021
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars
December 28, 2020
The antitumoral drug ABTL0812 shows promising results against neuroblastoma
December 16, 2020
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain
November 5, 2020
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell
October 22, 2020
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER
September 22, 2020
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal
June 9, 2020
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer
March 25, 2020
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company
September 12, 2019
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting
May 30, 2019
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812
February 4, 2019
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference
January 2019
AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre
December 5, 2018
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer
November 7, 2018
Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia
September 19, 2018
At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell
August 24, 2018
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer
February 19, 2018
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer
December 13, 2017
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France
October 5, 2017
Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer
September 18, 2017
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology
March 3, 2017
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer
December 14, 2016
Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients
November 22, 2016
· ABTL0812 is administered in combination with carboplatin and paclitaxel
· Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead the study, which includes other centers in Spain and France
· Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead the study, which includes other centers in Spain and France
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market.
May 11, 2016
Collaboration Boosts Development of a Fully Differentiated Inhibitor of the PI3K/Akt/mTOR pathway.
ABTL0812 is currently in Phase 2 Clinical Trials to Treat Lung and Endometrial Cancers.
ABTL0812 is currently in Phase 2 Clinical Trials to Treat Lung and Endometrial Cancers.
Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma.
April 7, 2015
Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014.
February 14, 2014
ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer
February 5, 2014
The Spanish Medicines Agency has approved the Initiation of the Phase I/Ib Clinical Trial at Hospital Clinic Barcelona.
Ability Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013.
February 20, 2013
ABILITY PHARMACEUTICALS awarded a 1.2 million euros grant to develop its Lipid Analog ABTL0812 for Lung and Pancreatic Cancer
February 5, 2013
The grant will fund the first-in-man phase Ib clinical trial in advanced cancer patients with refractory solid tumor
The program will be presented at the 2013 ASCO Meeting and involves the Autonomous University of Barcelona and the research institute IDIBAPS
The program will be presented at the 2013 ASCO Meeting and involves the Autonomous University of Barcelona and the research institute IDIBAPS
Ability Pharmaceuticals to Present at the Biotech Showcase Event (a Satellite to JP Morgan Healthcare Conference) in San Francisco, January 7-9, 2013.
December 23, 2012
AB-Therapeutics closes 1 million euro financing round and changes the company name to Ability Pharmaceuticals
September 21, 2012
The Catalan Biopharmaceutical company will use the new funds in the clinical development of its novel anticancer drug in lung and pancreatic cancer.
Inveready Seed Capital, Genoma España, shareholders, business angels and private investors participate in the funding.
Inveready Seed Capital, Genoma España, shareholders, business angels and private investors participate in the funding.
AB-Therapeutics to participate at the annual meeting of Association of Cancer Research (EACR) in Barcelona, Catalonia, Spain
June 29, 2012
During the congress the company will present new data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas, as well as data on toxicology and pharmacokinetics.
The work presented has been selected by the evaluation committee of the EACR.
The work presented has been selected by the evaluation committee of the EACR.
AB-Therapeutics to Exhibit at the BIO 2012 International Convention in Boston, June 18-21, 2012 and to Present at Satellite Events.
June 15, 2012
AB-Therapeutics to participate at the annual meeting of the American Association of Cancer Research (AACR) in Chicago (USA)
March 12, 2012
During the congress the company will present the first data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas.
The work presented has been selected by the evaluation committee of the AACR.
The work presented has been selected by the evaluation committee of the AACR.
AB-Therapeutics to Present at the 5th Annual European Life Science CEO Forum for Partnering & Investing in Zurich (Switzerland), March 6-7, 2012.
March 1, 2012
AB-Therapeutics participates in the 10th Venture Capital Forum NEOTEC
AB-Therapeutics Announces the Launch of its New Web Site www.ab-therapeutics.com
June 15, 2011
AB-Therapeutics Announces Participation In Bio 2011 Annual International Convention in Washington, DC
June 14, 2011
AB-Therapeutics hold the First Meeting of its international Scientific Advisory Board
June 1, 2011
AB-Therapeutics Hires José Alfón as Director of Development
January 3, 2011
Alfón, previously at Palau Pharma, will head the Catalan company’s R&D
AB-Therapeutics new anticancer compounds reduce by 70% lung tumors growth
November 8, 2010
The Barcelona based biotech company is in a series-A fundraising round to conduct preclinical development and to file an IND in late 2011
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona
June 29 , 2022
LATEST NEWS
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
